Abstract
Biologic therapy has increasingly been used in the treatment of chronic diseases. Tumor necrosis factor (TNF) is a cytokine implicated in the pathogenesis of rheumatoid arthritis and inflammatory bowel disease. Anti-TNF therapy is being used in the treatment of these conditions. Since the introduction of anti-TNF agents, there have been many case reports of development of malignancy after the initiation of anti- TNF therapy. With increasing case reports, there is growing concern that anti-TNF therapy, albeit useful in the treatment of these chronic conditions, might be associated with the development of malignancy in patients. In this review we examine the different anti-TNF agents and different studies to evaluate any possible association between use of any anti-TNF agent and development of malignancy.
Original language | English (US) |
---|---|
Pages (from-to) | 241-247 |
Number of pages | 7 |
Journal | Drug, Healthcare and Patient Safety |
Volume | 2 |
Issue number | 1 |
DOIs | |
State | Published - 2010 |
Externally published | Yes |
Keywords
- Inflammatory bowel disease
- Malignancy
- Rheumatoid arthritis
- Tumor necrosis factor inhibitor
ASJC Scopus subject areas
- Pharmacology
- Health Policy